The sharp revenue decline in the core VBAS business, particularly from international markets, signals a material operational setback. Monitor the next quarter for a recovery in international orders; a second consecutive decline would confirm a trend and likely pressure the stock further.
Price Chart
Executive Summary
Vycor Medical reported Q2 2026 revenue of $418,264, a 16% decline YoY, driven by a 17% drop in the core VBAS division's international sales. GAAP operating profit fell sharply to $6,851 from $51,146 in the prior year, and the company swung to a net loss of $(22,288) vs a profit of $23,887. The revenue decline and earnings reversal are the primary negative signals, outweighing modest growth in the NovaVision segment.
Key Financial Metrics
Key Facts
- Q2 2026 revenue fell 16% YoY to $418,264, driven by a 17% decline in Vycor Medical (VBAS) division revenue.
- GAAP operating profit collapsed to $6,851 from $51,146 in Q2 2025.
- Net income swung to a loss of $(22,288) from a profit of $23,887 in the prior-year quarter.
- Non-GAAP operating profit fell 73% to $22,952 from $85,712.
- The revenue decline was attributed to lumpy international sales; the company noted the decrease was 'all from international markets.'
Financial Impact
Revenue declined by $78,089 (16%) YoY, and GAAP operating profit decreased by $44,295 (87%).
Risk Factors
- Continued lumpiness in international sales could lead to further revenue volatility.
- The company remains unprofitable on a GAAP basis after preferred dividends, with a net loss available to common stockholders of $(22,288).
- The OTCQB listing and small revenue base ($418K/quarter) make the stock highly sensitive to single-quarter fluctuations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038366 |
| Document: form8-k.htm | 0001493152-26-038366 |
| Document: 0001493152-26-038366-index-headers.html | 0001493152-26-038366 |
| Document: 0001493152-26-038366-index.html | 0001493152-26-038366 |
| Document: 0001493152-26-038366.txt | 0001493152-26-038366 |
| 8-K Data (Synthetic) | 0001493152-26-038366 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $0.0690 $0.0670 | ▲ +2.90% | ▲ +1.37% | $0.0350 (+49.28%) |
May 15, 2026 23w ago | 8-K | $0.0700 $0.0700 | · 0.00% | ▼ −2.12% | $0.0350 (−50.00%) |
Mar 31, 2026 30w ago | 8-K | $0.0900 $0.0690 | ▼ −23.33% | ▼ −32.76% | $0.0350 (−61.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers